NovaGo Therapeutics
Schlieren, CH · Founded 2015 · 10 employees on LinkedIn · 1 known investors
Find your way into NovaGo Therapeutics
NovaGo Therapeutics is a biotech company developing antibody-based therapeutics to promote nerve repair and recovery following spinal cord injury. The company's candidates are designed to enhance nerve regeneration and functional recovery, with Phase 1 clinical trials expected to begin in 2024.
Investors · 1
Funding
SEC filings, press & company announcements$30M disclosed across 1 round · 2026
- $30MSeries BSep 2026 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
NovaGo Therapeutics secures 30 million dollars Series B fundingvir.com.vn · Sep 2026
NovaGo raises $30M to advance regenerative spinal cord therapy - European Biotechnology Magazineeuropean-biotechnology.com · Sep 2026
NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury - BioSpacebiospace.com · Sep 2026Frequently asked questions
- What does NovaGo Therapeutics do?
- NovaGo Therapeutics is a biotech company developing antibody-based therapeutics to promote nerve repair and recovery following spinal cord injury. The company's candidates are designed to enhance nerve regeneration and functional recovery, with Phase 1 clinical trials expected to begin in 2024.
- Who are NovaGo Therapeutics's investors?
- NovaGo Therapeutics's investors include Pureos Bioventures.
- How much funding has NovaGo Therapeutics raised?
- NovaGo Therapeutics has disclosed $30M raised across 1 round.
- Where is NovaGo Therapeutics headquartered?
- NovaGo Therapeutics is headquartered in Schlieren, CH.